<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43448">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01777425</url>
  </required_header>
  <id_info>
    <org_study_id>082012</org_study_id>
    <nct_id>NCT01777425</nct_id>
  </id_info>
  <brief_title>Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)</brief_title>
  <official_title>Long-term Control in Rhinosinusitis After FESS: Cross-sectional Observational Study on Control in Rhinosinusitis at a Mean Interval of 3 Years After FESS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      State-of-the-art documents like ARIA and european position paper on rhinosinusitis (EPOS)
      provide clinicians with evidence-based treatment algorithms for allergic rhinitis (AR) and
      chronic rhinosinusitis (CRS) respectively (1)(2) . The currently available medications can
      alleviate symptoms associated with AR and RS, and most patients with RS benefit from
      endoscopic sinus surgery (ESS). In real life, a significant percentage of patients with AR
      and CRS continue to experience bothersome symptoms despite adequate treatment. This group
      with so-called severe chronic upper airway disease (SCUAD) represents a therapeutic
      challenge (3).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Control Status of Patients With Rhinosinusitis</measure>
    <time_frame>3 years after FESS</time_frame>
    <safety_issue>No</safety_issue>
    <description>1. Percentage of patients with rhinosinusitis that are fully controlled, partly controlled and uncontrolled according to the new european position paper on rhinosinusitis (EPOS) definitions at a mean interval of 3 years after endoscopic sinus surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Control Nasal Endoscopy</measure>
    <time_frame>3 years after ESS</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluating of difference in control if nasal endoscopy is performed three years after ESS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual Analogue Scale (VAS), Sinonasal Outcome Test (SNOT22) and Short Form (36) Health Survey (SF36) Score Three Years After ESS in Controlled, Partially Controlled and Uncontrolled Group</measure>
    <time_frame>three years after ESS</time_frame>
    <safety_issue>No</safety_issue>
    <description>VAS scores: a measurement of patient's subjective evaluation by indicating a position on a line between two endpoints. Patients will score eight individual symptoms on a scale from 0 until 10, being 0 no trouble and 10 maximum trouble. Finally a mean symptom score will be calculated per symptom.
The SNOT-22 questionnaire is a validated 22 item questionnaire. patients indicate how much they are affected in eight different areas and identify the 5 most important items. The SNOT-22 total score can range from 0 to 110, with higher scores representing worse quality of life.
Perceived health status can be evaluated by the 36-item short-form (SF-36). It consists of 36 items covering eight domains. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">389</enrollment>
  <condition>Condition of Patient 3 Years After FESS-operation</condition>
  <arm_group>
    <arm_group_label>rhinosinusitis patients</arm_group_label>
    <description>patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        rhinosinusitis patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients that have undergone bilateral ESS for inflammatory sinonasal disease,
             without additional sino-nasal surgery after the ESS.

          2. Age &gt; 18 and &lt; 75 years.

          3. Written informed consent

          4. Dutch, French or English speaking patients

        Exclusion Criteria:

          1. Unilateral ESS

          2. Benign and malignant tumor disease

          3. Patient with a psychiatric, addictive, or any disorder of which the investigators
             feel at the time of evaluation for participation in the study that this may
             compromise the ability to give truly informed consent for participation in this study
             or provide reliable information on the questionnaire

          4. Lack of knowledge of Dutch, French or English
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hellings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven ORL</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <firstreceived_results_date>August 14, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rhinosinusitis Patients</title>
          <description>patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rhinosinusitis Patients</title>
          <description>patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="389"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="389"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47.3" spread="14.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="183"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="206"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Belgium</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="389"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Control Status of Patients With Rhinosinusitis</title>
        <description>1. Percentage of patients with rhinosinusitis that are fully controlled, partly controlled and uncontrolled according to the new european position paper on rhinosinusitis (EPOS) definitions at a mean interval of 3 years after endoscopic sinus surgery.</description>
        <time_frame>3 years after FESS</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Rhinosinusitis Patients and Status</title>
            <description>patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="389"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Control Status of Patients With Rhinosinusitis</title>
            <description>1. Percentage of patients with rhinosinusitis that are fully controlled, partly controlled and uncontrolled according to the new european position paper on rhinosinusitis (EPOS) definitions at a mean interval of 3 years after endoscopic sinus surgery.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>fully controlled three years after ESS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>partially controlled three years after ESS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>uncontrolled three years after ESS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control Nasal Endoscopy</title>
        <description>Evaluating of difference in control if nasal endoscopy is performed three years after ESS.</description>
        <time_frame>3 years after ESS</time_frame>
        <safety_issue>No</safety_issue>
        <population>fully controlled status with endoscopic evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Rhinosinusitis Patients</title>
            <description>patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Control Nasal Endoscopy</title>
            <description>Evaluating of difference in control if nasal endoscopy is performed three years after ESS.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>fully controlled status with endoscopic evaluation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>partially controlled status with endoscopy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>uncontrolled status wih endoscopic evaluation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Visual Analogue Scale (VAS), Sinonasal Outcome Test (SNOT22) and Short Form (36) Health Survey (SF36) Score Three Years After ESS in Controlled, Partially Controlled and Uncontrolled Group</title>
        <description>VAS scores: a measurement of patient’s subjective evaluation by indicating a position on a line between two endpoints. Patients will score eight individual symptoms on a scale from 0 until 10, being 0 no trouble and 10 maximum trouble. Finally a mean symptom score will be calculated per symptom.
The SNOT-22 questionnaire is a validated 22 item questionnaire. patients indicate how much they are affected in eight different areas and identify the 5 most important items. The SNOT-22 total score can range from 0 to 110, with higher scores representing worse quality of life.
Perceived health status can be evaluated by the 36-item short-form (SF-36). It consists of 36 items covering eight domains. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability</description>
        <time_frame>three years after ESS</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Rhinosinusitis Patients</title>
            <description>patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="389"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Analogue Scale (VAS), Sinonasal Outcome Test (SNOT22) and Short Form (36) Health Survey (SF36) Score Three Years After ESS in Controlled, Partially Controlled and Uncontrolled Group</title>
            <description>VAS scores: a measurement of patient’s subjective evaluation by indicating a position on a line between two endpoints. Patients will score eight individual symptoms on a scale from 0 until 10, being 0 no trouble and 10 maximum trouble. Finally a mean symptom score will be calculated per symptom.
The SNOT-22 questionnaire is a validated 22 item questionnaire. patients indicate how much they are affected in eight different areas and identify the 5 most important items. The SNOT-22 total score can range from 0 to 110, with higher scores representing worse quality of life.
Perceived health status can be evaluated by the 36-item short-form (SF-36). It consists of 36 items covering eight domains. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>VAS score controlled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.6" spread="7.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SNOT 22 score controlled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.2" spread="9.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SF36 score controlled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82.1" spread="14.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>VAS score partially controlled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.8" spread="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SNOT22 score partially controlled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.6" spread="12.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SF36 score partially controlled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.5" spread="16.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>VAS score uncontrolled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.2" spread="19.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SNOT22 score uncontrolled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.4" spread="19.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SF36 score uncontrolled group</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61.9" spread="19.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>patients had to fill in the questionnaire at home, with no help of an expert</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Dr. P. Hellings</name_or_title>
      <organization>UZ Leuven</organization>
      <phone>+3216332340</phone>
      <email>peter.hellings@uzleuven.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
